ATE195953T1 - Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c - Google Patents

Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c

Info

Publication number
ATE195953T1
ATE195953T1 AT95914048T AT95914048T ATE195953T1 AT E195953 T1 ATE195953 T1 AT E195953T1 AT 95914048 T AT95914048 T AT 95914048T AT 95914048 T AT95914048 T AT 95914048T AT E195953 T1 ATE195953 T1 AT E195953T1
Authority
AT
Austria
Prior art keywords
sub
seq
cytotoxic
peptides
virus
Prior art date
Application number
AT95914048T
Other languages
English (en)
Inventor
Francis V Chisari
Andreas Cerny
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22799919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE195953(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE195953T1 publication Critical patent/ATE195953T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95914048T 1994-03-17 1995-03-16 Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c ATE195953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/214,650 US5709995A (en) 1994-03-17 1994-03-17 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
PCT/US1995/003224 WO1995025122A1 (en) 1994-03-17 1995-03-16 Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus

Publications (1)

Publication Number Publication Date
ATE195953T1 true ATE195953T1 (de) 2000-09-15

Family

ID=22799919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914048T ATE195953T1 (de) 1994-03-17 1995-03-16 Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c

Country Status (7)

Country Link
US (2) US5709995A (de)
EP (1) EP0759937B2 (de)
JP (3) JP3844494B2 (de)
AT (1) ATE195953T1 (de)
CA (1) CA2184890C (de)
DE (1) DE69518642T3 (de)
WO (1) WO1995025122A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
CA2175692A1 (en) * 1993-11-04 1995-05-11 Geert Leroux-Roels Immunodominant human t-cell epitopes of hepatitis c virus
US6057294A (en) * 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
EP0921805A4 (de) * 1996-03-19 2002-06-26 Univ Virginia Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen
EP1767542B1 (de) * 1996-03-21 2016-05-11 Epimmune Inc. HLA-A2.1 bindende Peptide und deren Verwendung
BR9708220A (pt) * 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6685944B1 (en) * 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
EP1233982B1 (de) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neues nichtstrukturelles hcv polypeptid
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
EE200200444A (et) * 2000-02-21 2003-12-15 Pharmexa A/S Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
CA2409287A1 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2000275748A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2003301865A1 (en) * 2002-05-16 2004-06-07 The General Hospital Corporation Epitopes of hepatitis c virus
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2557164A1 (de) 2003-02-18 2013-02-13 Kevin M. Slawin Induzierte Aktivierung ein dendritischen Zellen
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
ATE489967T1 (de) * 2003-07-11 2010-12-15 Intercell Ag Hcv-vakzin
FR2862648B1 (fr) * 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2006124412A2 (en) * 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific t-cells
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR20080079243A (ko) * 2005-11-10 2008-08-29 유니버시티 오브 시카고 Ｈｃｖ-반응성 ｔ 세포 수용체
CN101336110B (zh) 2006-06-01 2011-06-01 程云 预防或治疗肝损伤的肽及其衍生物及其应用
AU2007310946B2 (en) 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
US8580270B2 (en) * 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
EP2462451B1 (de) * 2009-08-05 2016-02-17 Nexigen GmbH Mit hcv interagierende humane proteine und methoden für deren verwendung
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US20130183376A1 (en) 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
EP2760892A1 (de) 2011-09-29 2014-08-06 Apo-T B.V. Multispezifische bindungsmoleküle zur anzielung aberranter zellen
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
EP3456735A1 (de) * 2012-06-26 2019-03-20 Apo-T B.V. Auf krankheitserreger abzielende bindungsmoleküle
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
WO2016036746A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
EP3268014B1 (de) 2015-03-10 2022-09-21 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Gegen das bevorzugt exprimierte antigen von melanomen gerichtete t-zell-rezeptoren und verwendungen davon
WO2017180420A1 (en) * 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
CN109963587A (zh) 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
EP3621988A1 (de) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Verfahren zur verstärkung oder änderung der signaltransduktion
EP3720479A2 (de) 2017-12-08 2020-10-14 Bellicum Pharmaceuticals, Inc. Verfahren zur steigerung und erhaltung der wirksamkeit von car-t-zellen
AU2021397278A1 (en) * 2020-12-09 2023-07-06 Tevogen Bio Inc. Virus specific t-cells and methods of treating and preventing viral infections

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
DK154394C (da) * 1982-10-21 1989-04-24 Apv Pasilac As Fremgangsmaade til at foroege kapaciteten af anlaeg for membranfiltrering af maelk eller maelkeprodukter til foderstoffer eller vaekstmedier.
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4625918A (en) * 1983-07-29 1986-12-02 Diesel Kiki Co., Ltd. Fuel injection valve
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
JPH0454197A (ja) * 1990-06-19 1992-02-21 Chemo Sero Therapeut Res Inst Ｃ型肝炎ウイルス抗体検出用合成ペプチド抗原、その組成物およびその使用方法
NZ238681A (en) * 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
HU227547B1 (en) * 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ES2287969T3 (es) 1992-03-06 2007-12-16 Innogenetics N.V. Peptidos de vih.
US5980899A (en) 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
CA2175692A1 (en) * 1993-11-04 1995-05-11 Geert Leroux-Roels Immunodominant human t-cell epitopes of hepatitis c virus
EP0754193B1 (de) * 1994-04-08 2000-06-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes

Also Published As

Publication number Publication date
US20020115061A1 (en) 2002-08-22
JP4394019B2 (ja) 2010-01-06
JP3844494B2 (ja) 2006-11-15
DE69518642D1 (de) 2000-10-05
DE69518642T2 (de) 2001-05-03
CA2184890C (en) 2011-05-24
JPH09510455A (ja) 1997-10-21
JP2006265264A (ja) 2006-10-05
WO1995025122A1 (en) 1995-09-21
JP4463786B2 (ja) 2010-05-19
EP0759937A1 (de) 1997-03-05
US7220420B2 (en) 2007-05-22
EP0759937B1 (de) 2000-08-30
US5709995A (en) 1998-01-20
EP0759937B2 (de) 2008-12-31
DE69518642T3 (de) 2009-05-14
CA2184890A1 (en) 1995-09-21
JP2005247852A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
ATE195953T1 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
RU2212899C2 (ru) Hcv иммунореактивные полипептидные композиции
EP0979867A3 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
NO905438L (no) Virusmiddel.
RU98117084A (ru) Hcv иммунореактивные полипептидные композиции
BG96943A (bg) Състави от антигени на хепатит-с вирус за използуване при имуноизследване за анти-нсv антитела
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
EP1004670A3 (de) Hepatitis C Virus Genotypsequenzen sowie ihre Verwendung als Behandlungs- und Nachweismittel
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
CA2108466A1 (en) Hcv genomic sequences for diagnostics and therapeutics
MY104208A (en) Non-a, non-b hepatitis virus antigen peptide.
DE69029092D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
DE69232906D1 (de) Detektion des Hepatis-C Virus.
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
DE60036881D1 (de) Neues nichtstrukturelles hcv polypeptid
DE69133552D1 (de) Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
Honda et al. Sequence comparisons for a hepatitis C virus genome RNA isolated from a patient with liver cirrhosis
KR920703640A (ko) 비a비b형 간염 바이러스 항원 단백질
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
ATE115964T1 (de) Non-a non-b sequenzen.
KR950000880A (ko) 한국형 씨(c)형 간염 바이러스의 일종인 케이에이치씨브이-엘2(khcv-l2)의 전체 뉴클레오티드서열 및 이로부터 유추된 아미노산 서열
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열
IT1270941B (it) Peptidi di hcv e loro usi.
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties